

**Mycobacterial mycolic acids as
immunoregulatory lipid antigens in the
resistance to tuberculosis**

By Dismore Gilbert Ramathudi Siko

**Submitted in partial fulfillment of the requirements for the degree
of**

Doctor of Philosophy

in the Faculty of Natural and Agricultural Sciences

Department of Biochemistry

University of Pretoria

October 2002

Acknowledgements:

I acknowledge with gratitude the following persons and institutions for their support :
Firstly I wish to thank the All Mighty, the Alpha and the Omega. With faith in God and Christ anything is possible.

My promoter and tutor Prof. Jan Verschoor for giving me the opportunity to pursue this field of study and his unfailing guidance.

My co-promoter Dr Ela Johannsen for her encouragement, advice, guidance and microbiology expertise.

Professor Rob Benner and members of the Immunology Department at Erasmus University Rotterdam, Holland for inviting and accommodating me in his department.

Dr. Vincent Vandervelden for his assistance and accommodation in his laboratory during my stay in Holland.

Dr Annemieke Ten Bokum for her academic input, insight and guidance.

Sandra van Wyngaardt for her indispensable assistance and just for being her.

Kobus Venter for the splendid work with the animals and the humour.

Members of the TB team past and present for the best teamwork.

My parents, members of my family and my friends for being there for me always.

My church, for bringing me closer to the Lord.

Financial assistance from, Adcock Ingram Limited, National Research Foundation (NRF), Medical Research Council (MRC), and Erasmus University Rotterdam (EUR).

“Morena ke modisa wa ka ga nkitla ke tlhoka sepe, o ntsamaisa mo mafulong a matalana”



Table of Contents	Page
List of Abbreviations	viii
List of Figures	xiv
List of Tables	xxi
1 CHAPTER 1: General introduction	1
1.1 Tuberculosis history	1
1.2 Mycobacterium tuberculosis	3
1.3 Tuberculosis: an emergency that does not cease	5
1.4 Tuberculosis and HIV	7
1.5 Infection and transmission of <i>M. tuberculosis</i>	8
1.6 Tuberculosis	10
1.6.1 Stages of tuberculosis	11
1.7 Tuberculosis immunity	12
1.8 Cell-mediated immune response	13
1.8.1 CD4+ T-cells in tuberculosis	14
1.8.2 CD8+ T-cells in tuberculosis	14
1.8.3 Double-negative $\alpha\beta$ T-cells	15
1.8.4 $\gamma\delta$ T-cells in tuberculosis	15
1.8.5 Other cells in tuberculosis	16
1.9 Cholesterol and mycobacterial survival	18
1.10 The macrophage (M Φ)	19
1.10.1 Macrophage (M Φ) activation	20
1.10.2 Fate of intracellular <i>M. tuberculosis</i> in the M Φ	20
1.11 Inflammation	22
1.12 Cytokines	22
1.12.1 Interleukin-1	25
1.12.2 Interleukin-4	25



1.12.3	Interleukin-10	26
1.12.4	Interleukin-12	26
1.12.5	Interferon-gamma (IFN- γ)	28
1.12.6	Tumour necrosis factor-alpha (TNF- α)	29
1.13	Tuberculosis control	30
1.13.1	Tuberculosis notification and treatment	31
1.13.2	Tuberculosis diagnosis	33
1.13.2.1	Tuberculin test	33
1.13.2.2	Acid-fast staining	33
1.13.2.3	Chromatographic identification	34
1.13.2.4	DNA based techniques	34
1.13.2.5	The demand for a serodiagnostic tuberculosis test	35
1.14	Mycobacterial mycolic acids in tuberculosis resistance	35
1.15	Perspectives of this study	36
2	CHAPTER 2: Mycolic acids-induced cytokines in <i>M. tuberculosis</i>-infected mice	38
2.1	Introduction	38
2.1.1	Cytokine profiling	38
2.1.2	Quantitative cytokine analysis	39
2.2	Study Approach	42
2.3	Aims:	42
2.4	Materials	43
2.4.1	Bacteria	43
2.4.2	Animals	43
2.4.3	Reagents	43

2.5	Methods	45
2.5.1	Preparation of mycobacteria or Preparation of mycobacterial suspensions	45
2.5.2	Mycolic acids preparation	45
2.5.3	Treatment, infection and preparation of the organs	47
2.5.4	RNA extraction and quantification	48
2.5.5	End-point Semi-quantitative reverse transcriptase polymerase chain reaction (SQ-RT-PCR)	48
2.5.6	Real-time quantitative PCR	49
2.6	Results	51
2.6.1	Interleukin-12 (IL-12) mRNA expression	52
2.6.2	Interferon gamma (IFN- γ)	54
2.6.3	Tumour necrosis factor-alpha (TNF- α) expression	56
2.6.4	Interleukin-4 (IL-4) expression	57
2.6.5	Granulocyte monocyte colony-stimulating factor (GM-CSF) mRNA expression	58
2.6.6	The T-helper-1/ helper-2 bias	59
2.7	Discussion	61
3	Chapter 3: Mycolic acids cytokine response during the combined murine AIDS and <i>M. tuberculosis</i> infection	64
3.1	Introduction	64
3.1.1	Animal models	65
3.1.2	Murine AIDS	66
3.1.3	Immune response during MAIDS	67
3.1.4	Cytokines in MAIDS	69
3.2	Aims	71
3.3	Materials	72
3.3.1	Bacteria	72
3.3.2	Virus	72
3.3.3	Animals	72
3.3.4	Reagents	72

3.4	Methods	74
3.4.1	Virus preparation	74
3.4.2	Bacterial culture	74
3.4.3	Mycolic acids preparation	75
3.4.4	Infection and treatment	75
3.4.5	Organ preparation and survival study	75
3.4.6	RNA preparation	76
3.4.7	Real-time PCR	76
3.5	Results	77
3.5.1	Survival study	77
3.5.2	Mycolic acids induced cytokine responses during tuberculosis in immuno-compromised animals	78
3.5.2.1	Interleukin-12 (IL-12) mRNA expression	79
3.5.2.2	Interferon-gamma (IFN- γ) mRNA expression	81
3.5.2.3	Interleukin-10 (IL-10) mRNA expression	82
3.5.2.4	Anti-inflammatory IL-10/ Pro-inflammatory IL-12 and IFN- γ ratios	85
3.6	Discussion	88
4	Chapter 4: Combination of chemotherapy with mycolic acids during treatment of <i>M. tuberculosis</i> infected Balb/c mice	92
4.1	Introduction	92
4.1.1	Anti-tuberculosis drugs	92
4.1.2	T-cell mediated immunity and tuberculosis chemotherapy	94
4.2	Aims	96
4.3	Materials	97
4.3.1	Cultures	97
4.3.2	Growth medium used for the cultivation of <i>M. tuberculosis</i>	97



4.3.3	Reagents	97
4.3.4	Washing and dilution of <i>M. tuberculosis</i>	98
4.3.5	Antibiotics	98
4.3.6	Preparation of organ homogenates	98
4.3.7	Blood decontamination	99
4.3.8	Experimental animals	99
4.3.9	Plasticware	100
4.3.10	Preparation of organ homogenates	100
4.4	Methods	101
4.4.1	Cultivation of bacteria	101
4.4.2	Viable bacterial counts	101
4.4.3	Preparation of mycolic acids from bacterial samples	102
4.4.4	Preparation of conjugates	102
4.4.5	Preparation of bacterial suspensions	102
4.4.6	Experimental animals	103
4.4.7	Inoculation with <i>M. tuberculosis</i> H37 Rv suspensions	104
4.4.8	Introduction of MA-serum conjugate and mouse serum	104
4.4.9	Administration of antibiotics	104
4.4.10	Preparation of organ homogenates	105
4.4.11	Decontamination of organ homogenates	106
4.4.12	Plating of decontaminated homogenates	107
4.4.13	Experimental set-up	108
4.5	Results	109
4.5.1	Confirmation of doses of <i>M. tuberculosis</i> and mycolic acids	109
4.5.2	Comparison of the masses of the removed organs	109
4.5.3	Mycobacterial cell counts at week 54	115
4.6	Discussion	118



5 Chapter 5: Development of a biosensor antibody assay for <i>Mycobacterium tuberculosis</i> mycolic acids	120
5.1 Introduction	120
5.1.1 Modern advances in immunoassays	120
5.1.2 The Resonant mirror biosensor	121
5.2 Aims	126
5.3 Materials	127
5.3.1 Mycolic acids	127
5.3.2 Reagents	127
5.3.3 Resonant Mirror Biosensor apparatus	128
5.3.4 Human sera	128
5.3.5 Liposomes	129
5.3.6 ELISA	129
5.4 Methods	130
5.4.1 Mycobacterial culture	130
5.4.2 Mycolic acids preparation	130
5.4.3 Liposomes	131
5.4.4 ELISA	131
5.4.5 Coating of biosensor cuvettes	133
5.4.5.1 Coating of the hydrophobic cuvette	133
5.4.5.2 Coating of underivatized cuvettes with liposomes	134
5.4.6 Binding of human antibodies in the biosensor	134
5.4.7 Inhibition of antibody binding by pre-incubation with liposomes	135
5.4.8 Washing and regeneration of biosensor cuvettes	135
5.5 Results	136
5.5.1 Anti-mycolic acids antibodies on a hydrophobic cuvette	136



5.5.2	ELISA confirmation of the cholesterol and mycolic acids cross-reactivity	138
5.5.3	Modeling of the possible molecular structural mimicry between cholesterol and mycobacterial mycolic acids	140
5.5.4	Coating the underivatized cuvettes with mycolic acids	142
5.5.5	Inhibition tests	147
5.5.6	Cholesterol-mycolic acids interactions	151
5.6	Discussion	154
<hr/>		
6	CHAPTER 6: General Discussion	157
6.1	Mycolic acids in murine tuberculosis	159
6.2	Mycolic acids in immunocompromised mice	160
6.3	Immunotherapy with mycolic acids	162
6.4	Mycolic acids in a biosensor based serodiagnostic assay for tuberculosis	163
6.5	Conclusion	164
<hr/>		
	Summary	167
<hr/>		
	Opsomming	169
<hr/>		
	References	171
<hr/>		

List of Abbreviations

β2M	Beta-2-microglobulin
$\gamma\delta$	Gamma-delta
<u>A</u>	
AIDS	Acquired immune deficiency syndrome
AM	Alveolar macrophage
APC	Antigen presenting cell
ATCC	American Type Culture Collection
<u>B</u>	
BCG	Bacillus Calmette-Guérin
<u>C</u>	
CAM	Cytokine-activated monocytes
CD	Cluster of differentiation
cDNA	Complementary deoxyribonucleic acid
CFU	Colony forming units
Chol	Cholesterol
CMI	Cell-mediated immunity
<u>D</u>	
DEPC	Diethyl pyrocarbonate
DN	Double negative
DNA	Deoxyribonucleic acid
DOTS	Directly observed treatment short course



DTH	Delayed-type hypersensitivity
<u>E</u>	
<i>E. coli</i>	<i>Eschirichia coli</i>
EDTA	Ethylenediaminetetra-acetic acid
ELISA	Enzyme-linked immunosorbent assay
EMB	Ethambutol
<u>G</u>	
GAP-DH	Glyceraldehyde-3-phosphate dehydrogenase
GLC	Gas-liquid chromatography
GLP	Good laboratory practise
GM-CSF	Granulocyte macrophage colony stimulating factor
<u>H</u>	
HCl	Hydrochloric acid
HEPA	High Efficiency Particulate Air
HIV	human immunodeficiency virus
HPLC	High-performance liquid chromatography
<u>I</u>	
i.n.	Intranasal
i.p.	Intraperitoneal
i.v.	Intravenous
IFN-γ	Interferon gamma
IgG	immunoglobulin G
IL-	Interleukin



INH	Isiniazid
iNOS	Inducible nitric oxide synthase
IRMA	Immunoradiometric assay
<u>K</u>	
KOH	Potassium hydroxide
<u>L</u>	
LAM	lipoarabinomannan
LDL	Low-density lipoproteins
LPS	lipopolysaccharides
<u>M</u>	
<i>M. avium</i>	<i>Mycobacterium avium</i>
<i>M. bovis</i>	<i>Mycobacterium bovis</i>
<i>M. leprae</i>	<i>Mycobacterium. leprae</i>
<i>M. tuberculosis</i>	<i>Mycobacterium tuberculosis</i>
M.tb	<i>Mycobacterium tuberculosis</i>
MA	Mycolic acids
MAIDS	Murine acquired immunodeficiency syndrome
MCF	Mink cell focus forming
MDR TB	Multi-drug resistant tuberculosis
MgCl₂	Magnesium chloride
MHC	Major histocompatibility complex
MOPS	3-(<i>N</i> -morpholino) propanesulfonic acid
MOTTS	Mycobacteria Other Than Tuberculosis



MRC	Medical Research Council
mRNA	Messenger RNA
MuLV	Murine leukemia virus
MΦ	Macrophage
<u>N</u>	
NAC	No amplification control
NaCl	Sodium chloride
NALC-NaOH	N-acetyl-L-cysteine-sodium hydroxide
NaOH	Sodium hydroxide
NK	Natural killer cells
NKSF	Natural killer cell stimulatory factor
NO	Nitric oxide
NTC	No template control
<u>O</u>	
OD	Optical density
<u>P</u>	
PBS/AE	Phosphate buffered saline azide EDTA
PC	Phosphatidyl choline
PCR	Polymerase chain reaction
PMBC	Peripheral blood mononuclear cells
PPD	Purified protein derivative
PZA	Pyrazinamide

R

RFP	Rifampetine
RIA	Radioimmunoassay
RIF	Rifampicin
RNA	Ribonucleic acids
RNI	Reactive nitrogen intermediates
ROI	Reactive oxygen intermediates
RQ-PCR	Real time quantitative PCR
RQ-RT-PCR	Real-time quantitative reverse transcriptase PCR
rRNA	Ribosomal ribonucleic acids
RT	Reverse transcriptase
RT-PCR	Reverse transcriptase PCR
RZL	Rifalazil
<u>S</u>	
Sal	Saline
SC-1	Stromal cell line
Ser	Serum
SIV	Simian immunodeficiency virus
SM	Streptomycin
SOD	Superoxide dismutase
SQ-RT-PCR	Semi-Quantitative RT-PCR



SR	Scavenger receptor
<u>T</u>	
TB	Tuberculosis
TCR	T cell receptor
Th	T helper
TNF-α	Tumor necrosis factor alpha
<u>W</u>	
WHO	World Health Organisation

List of Figures

	Page
Figure 1.1: Electron micrographs of bacteria indicating the difference in appearances. Gram-positive bacteria (<i>S. aureus</i>) is ...	4
Figure 1.2: Bacterial cell walls of Gram-positive organisms (A), Gram-negative organisms with a double lipid layer (B) ...	5
Figure 1.3: Countries with most tuberculosis cases in the world.	7
Figure 1.4: Mechanism of <i>M. tuberculosis</i> survival and escape into the cytoplasm.	9
Figure 1.5: Factors that determine transmission of infection from a source case to contacts and the natural history of tuberculosis in infected ...	10
Figure 1.6: Mycobacterial evasion of the host macrophage.	18
Figure 1.7: Model of the bi-directional cellular and cytokine interactions between T-cell subsets and macrophages (M Φ) ...	24

Figure 1.8: World distribution of notified tuberculosis cases by World Health Organisation (WHO) region. AFR-sub-Saharan ...	32
Figure 2.1: The 5' nuclease activity of the DNA polymerase enzyme exploited to detect amplified DNA	41
Figure 2.2: Schematic representation of normalised reporter (Rn) versus cycle number	41
Figure 2.3: Survival of BALB/c mice infected intranasally with 2.5×10^5 <i>M. tuberculosis</i> H37Rv after pre-treatment ...	51
Figure 2.4: Relative IL-12 levels in the lungs of Balb/c mice removed five weeks after <i>M. tuberculosis</i> infection....	53
Figure 2.5: Relative IFN- γ levels in the lungs of Balb/c mice removed after five weeks of infection. The cytokine ...	55
Figure 2.6: Relative TNF- α levels in the lungs of Balb/c mice removed after five weeks of infection. The cytokine was ...	56
Figure 2.7: Relative IL-4 levels in the lungs of Balb/c mice removed after five weeks of infection. The cytokine was ...	57

Figure 4.4: Organ indices of the spleens and lungs removed from Balb/c mice and expressed as a percentage of ...	113
Figure 5.1: Target molecule delivery to the biosensor surface in either A) a micro cuvette or ...	122
Figure 5.2: Flow system biosensor with the direction of the flow relative to the angle of the incidence ...	123
Figure 5.3: Representation of the IAsys resonant mirror-sensing device built in a cuvette.	124
Figure 5.4: Schematic representation of the IAsys cuvette system with the vibro stirrers and oscillating laser light.	125
Figure 5.5: Binding profile of tuberculosis patient serum (TB) and negative control serum (Control) on a pre-derivatised ...	137
Figure 5.6: Binding profile of tuberculosis patient serum (TB) on a hydrophobic cuvette coated with mycolic acids ...	138
Figure 5.7: Antibodies binding profile on ELISA plates coated with either cholesterol (Chol) or mycolic acids (MA)....	139

Figure 5.8: The structures representing the proposed possible molecular mimicry between the methoxy-mycolic acids ...	141
Figure 5.9: Mycolic acids-cholesterol liposomes (PC 60) coated on a non-derivatised cuvette activated ...	143
Figure 5.10: Titration of saponin on a non-equilibrated mycolic acids-cholesterol PC60 liposome surface.	144
Figure 5.11: Depletion of mycolic acids on the liposome-coated surface due to continued regeneration ...	145
Figure 5.12: Resonant mirror biosensor binding profiles of tuberculosis patient (TB) and healthy control (Control) sera ...	146
Figure 5.13: Inhibition assay of TB patient sera with mycolic acids on a mycolic acids coated surface. TB patient serum of the ...	148
Figure 5.14: Inhibition assay of negative control sera with mycolic acids on a mycolic acids coated surface. The negative ...	149
Figure 5.15: Inhibition assay of tuberculosis sera with mycolic acids on a cholesterol coated surface. The tuberculosis ...	150

Figure 5.16: Binding assay of mycolic acids on a cholesterol-coated surface.	151
Figure 5.17: Binding assay of cholesterol on a mycolic acids -coated surface.	152
Figure 5.18: Biosensor binding profile of an inhibition assay of TB	153

List of Tables

	Page
Table 1.1: Cells involved in specific and non-specific defence against <i>M. tuberculosis</i>	17
Table 2.1 Murine Pre-Developed TaqMan Assay reagent plate	50
Table 3.1: Comparisons of MAIDS and AIDS	67
Table 4.1: Drugs recommended for tuberculosis short course treatment	94
Table 4.2: Experimental set-up of the chemotherapy experiment groups	108
Table 4.3: Average number of colony forming units recovered from the suspensions of the lungs and of the spleens 16-weeks.after infection	112
Table 4.4: Average number of colony forming units recovered from the suspension of the lungs and of the spleens 37 weeks after infection	114
Table 4.5: The calculated average from groups with positive mycobacterial counts	115
Table 4.6: Average number of colony forming units recovered from the suspension of the lungs and of the spleens 54 weeks after infection	116

Summary: Mycobacterial mycolic acids as immunoregulatory lipid antigens in the resistance to tuberculosis

By: Dismore Gilbert Ramathudi Siko
Promoter: Prof. Dr. J.A. Verschoor
Co-promoter: Dr E. Johannsen
Department: Biochemistry
Qualification: Doctor Philosophiae (Biochemistry)

Tuberculosis has returned with vengeance mainly due to the resurgence of multi drug resistant strains incurred by non-compliance to the 6-9 months chemotherapy programme. Co-infection with HIV, which disorientates the immune response, has aggravated the situation. This study was built on previous observations that indicated that the major lipid cell wall component of *M. tuberculosis*, i.e. mycolic acids, a wax that envelopes and protects the bacillus from the hostile host immune system, can be purified and administered to animals for protection against subsequent tuberculosis induction. It was established in this study that mycolic acids pre-treatment can significantly protect mice upon subsequent intranasal infection with *M. tuberculosis* and that this protection is not attributed so much to the T helper cell immunity, but rather through induction of innate immunity. In the murine AIDS model, innate immunity induced by mycolic acids pre-treatment was not enough to protect the virally immunocompromised mice against subsequent *M. tuberculosis* infection. Mycolic acids administration in mice did not support tuberculosis chemotherapy to enable shortening of the duration of chemotherapy. In human tuberculosis patients, antibodies to mycolic acids could be measured in a specially adapted configuration of a resonant mirror biosensor. The preliminary investigation opened up the possibility that the prevalence of anti-mycolic acids

antibodies in tuberculosis patients may be measured as a surrogate marker for tuberculosis infection. An apparent cross-reactivity between mycolic acids and cholesterol in binding to tuberculosis patient antibodies may provide far reaching insight in the role of the mycolic acids in the cell wall to facilitate infection. This research contributed significantly to the understanding of the host-pathogen interaction in tuberculosis, to open up fresh approaches to improved diagnosis and chemotherapy.

Opsomming: Mikobakteiële mikolsure as immunregulatariese lipied-antigene in die weerstandigheid teen tuberkulose.

Deur: Dismore Gilbert Ramathudi Siko
Promotor: Prof. Dr. J.A. Verschoor
Medepromotor: Dr. E. Johannsen
Departement: Biochemie
Kwalifikasie: Doctor Philosophiae (Biochemie)

Tuberkulose is terug met mening, hoofsaaklik vanweë die herlewing van multi-drogero-weerstandige patoogstamme deur die onvoldoening aan die 6-9 maande lange chemoterapie-termyn. Ko-infeksie met HIV, wat die immuunrespons verstoer, het die toestand vererger. Hierdie studie is gebaseer op vroeëre waarnemings wat daarop gedui het dat die dominante lipied-selwandkomponent van *M. tuberculosis*, d.i. mikolsure - 'n was wat die basillus omhul en beskerm teen die vernietigende immuunstelsel van die gasheer - gesuiwer en toegedien kan word aan proefdiere om beskerming te verleen teen daaropvolgende tuberkulose-induksie. Daar is met hierdie studie vasgestel dat voor-infeksie behandeling met mikolsure muise aansienlik kan beskerm teen daaropvolgende intranasale infeksie met *M. tuberculosis* en dat hierdie beskerming nie soseer te wyte is aan die T-helpersel-immuniteit nie, maar eerder deur die induksie van ingeskape immuniteit. In die muis-VIGS-model, was die ingeskape immuniteit, geïnduseer deur voorbehandeling met mikol-suur, onvoldoende om teen *M. tuberculosis* infeksie te beskerm in die virale immuunverdelde muis. Toediening van mikolsure aan muise het nie die effektiwiteit van chemoterapie ondersteun om 'n verkorte duur daarvan moontlik te maak nie. In mens tuberkulose-pasiënte kon teenliggame teen mikolsure aangetoon word in 'n spesiaal aangepaste konfigurasie van die resonante spieëlbiosensor. Die voorlopige ondersoek het die moontlikheid onthul dat die bestaan van anti-mikol-suur-teenliggame in tuberkulose pasiënte gemeet kan word as 'n surrogaatmerker van tuberkulose infeksie. 'n Oënskynlike kruis-reaktiwiteit tussen mikolsure- en cholesterol-binding aan tuberkulose-pasiënt-teenliggame kan verreikende insig verleen aan die rol

van mikosure in die selwand om infeksie te bevorder. Hierdie navorsing het bygedra tot 'n beter begrip van die gasheer-patogeen interaksie in tuberkulose, ten einde vars benaderings te skep vir verbeterde diagnose en chemoterapie.

